

MOST Signature

Model Portfolio

May 2025





Sector View

Sector	View
Automobiles	UW
Banks-Private	UW
Banks-PSU	OW
Capital Goods	OW
Cement	UW
Chemicals	N
Consumer	UW
EMS	N
Healthcare	OW
Infrastructure	OW
Insurance	N
Logistics	N

Sector	View
Media	N
Metals	UW
NBFC	OW
Oil & Gas	UW
Others	N
Real Estate	UW
Retail	UW
Staffing	N
Technology	N
Telecom	OW
Utilities	UW

OW: Overweight; **N:** Neutral; **UW:** Underweight

Portfolio Investment Characteristics

- A dynamic portfolio with a mix of Large and Mid-Caps
- Large Caps & Mid-caps with 5% weight each.
- Focused basket of 10-15 companies
- Stocks selected based on fundamentals, short term triggers, events, results, and news flows
- Regular review and performance update



Performance

Portfolio Performance

	1m	3m	6m	Since inception*
MOST Signature	4.5%	0.1%	-13.0%	0.2%
Nifty 200	6.4%	2.7%	-2.6%	8.8%

* Inception date: 10-May-2024
Absolute returns as on 7-May-2025
Returns are post expenses and includes dividends

Last few exits

Scrip Name	Buy Price	Sell Price	Gain/Loss
DIVISLAB	4,499	5,483	22%
INDIGO	4,395	5,297	21%
LT	3,277	3,321	1%
COFORGE	7,525	6,608	-12%
ANANTRAJ	885	449	-49%

Last 5 entries

Scrip Name	Buy Price	Allocation
HINDPETRO	358	5%
POWERGRID	294	5%
HAL	4,470	5%
NIVABUPA	81	5%
POLYCAB	5,887	5%

Price performance of Recommendations

Model Portfolio				
Scrip Name	Weight	Reco Price	Price (7th May'25)	Gain/Loss
KAYNES	5%	4,353	5,842	34%
ICICIBANK	5%	1,118	1,435	28%
DIVISLAB	5%	4,991	6,148	23%
ETERNAL	5%	204	237	16%
TATACONSUM	5%	1,023	1,146	12%
HINDPETRO	5%	358	397	11%
VBL	5%	481	512	6%
POWERGRID	5%	294	311	6%
JKCEMENT	5%	4,898	5,049	3%
SHRIRAMFIN	5%	625	637	2%
M&M	5%	3,109	3,120	0%
NIVABUPA ★	5%	81	81	0%
HAL ★	5%	4,470	4,470	0%
POLYCAB ★	5%	5,887	5,887	0%
CASTROLIND	5%	203	199	-2%
MAXHEALTH	5%	1,198	1,152	-4%
MANKIND	5%	2,562	2,432	-5%
AMBER	5%	6,375	5,983	-6%
INDHOTEL	5%	852	766	-10%
CAMS	5%	5,212	3,643	-30%

★ Denotes New Entry

Model Portfolio Recommendation


Model Portfolio				
Sector	Stocks	Weight	Market Cap	CMP (Rs)
Banking & Finance	ICICIBANK	5%	Large Cap	1,435
	SHRIRAMFIN	5%	Large Cap	637
	CAMS	5%	Mid Cap	3,643
	NIVABUPA ★	5%	Mid Cap	81
Automobile	M&M	5%	Large Cap	3,120
Healthcare	DIVISLAB	5%	Large Cap	6,148
	MANKIND	5%	Large Cap	2,432
	MAXHEALTH	5%	Large Cap	1,152
Industrials	HAL ★	5%	Large Cap	4,470
	KAYNES	5%	Mid Cap	5,842
	JKCEMENT	5%	Mid Cap	5,049
	POLYCAB ★	5%	Large Cap	5,887
	AMBER	5%	Mid Cap	5,983
Consumption	TATACONSUM	5%	Large Cap	1,146
	VBL	5%	Large Cap	512
Oil & Gas	CASTROLIND	5%	Mid Cap	199
	HINDPETRO	5%	Mid Cap	397
Digital	ETERNAL	5%	Large Cap	237
Utilities	POWERGRID	5%	Large Cap	311
Tourism	INDHOTEL	5%	Large Cap	766
Total		100%		

★ Denotes New Entry




Sector and Market cap Allocation

Sector Allocation



Market-Cap Allocation



Key Rationales



Steady quarter; robust other income drives earnings beat

- ICICI Bank reported a robust Q4 performance with PAT ₹126b (18% YoY growth), driven by NIM expansion, healthy other income, controlled provisions and contained operating expenses.
- ICICI Bank posted 11% YoY NII growth with NIM rising by 16bp QoQ to 4.41%. Net advances grew 13% YoY, while deposits rose 14% YoY. Secured asset quality remained stable (excl. agri) with no signs of stress, leading to an improvement in the GNPA ratio.
- We upgrade our earnings estimates for FY26/FY27 on the back of positive NIM surprise and controlled credit cost. We thus estimate RoA/RoE of 2.3%/17.5% in FY27. ICICI remains our top pick in the sector with a TP of ₹1,650.

Key Rationales



Building blocks; outperformance to sustain

- SHFL's 4QFY25 PAT grew 10% YoY to INR21.4b (in-line), with FY25 PAT (excl-exceptional) up 15% YoY. NII rose 9% YoY, but credit costs increased 12% QoQ to 2.4%. NIM compressed ~25bp QoQ to 8.25% due to excess liquidity, expected to normalize in 1-2 quarters.
- Management sees stable credit costs ahead. AUM growth guidance remains 15%+ for FY26, with cost-to-income ratio likely falling to 27-28%.
- SHFL's diversified mix, strong liability access, and cross-selling potential position it well. We expect ~17% AUM/~19% PAT CAGR (FY25-27E) and RoE of ~17%. We expect SHFL to emerge as a strong player across all its product segments.

Key Rationales



Building blocks; outperformance to sustain

- CAMS reported operating revenue of INR3.6b in 4QFY25 (7% beat), up 15% YoY. EBITDA increased 11% YoY to INR1.6b, reflecting EBITDA margin of 44.7% (est. 40.7%).
- The non-MF business recorded a revenue run rate of ~INR2b in FY25, with management projecting 25% growth in FY26, driven mainly by CAMSPay, AIF, and KRA, which would add around INR500m. Despite weak market sentiment in 4QFY25, SIP flows for the industry have been healthy.
- With a recovery in markets, the momentum should improve. We expect revenue/PAT to post a CAGR of 12%/13% over FY25-27E and reiterate a BUY rating on the stock. Recent correction gives an opportunity to buy given its duopoly nature, high entry barriers, low risk of mkt. share loss and high customer ownership.



**Steady quarter; robust
other income drives
earnings beat**

Key Rationales

- Niva Bupa reported 18%/25% YoY growth in GWP/NWP in Q4, driven by 3%/59%/18% growth in retail health /group health/PA businesses. It secured business from 2 large corp. accounts, significantly contributing to strong growth in group health.
- With a YoY expansion of 50bp/190bp in commission/expense ratios, the combined ratio improved to better-than-expected 92.8%, up 340bp YoY.
- We believe Niva is well-positioned to harness growth opportunities with a strategic global partner, a growing customer base, and innovative product offerings. The diversified channel mix will ensure improved scalability as the company moves toward geographic expansion.

Key Rationales

- M&M reported robust performance in Q4, led by a strong margin beat in FES segment (at 19.4% vs 17.3% est.). Revenue grew 24.5% YoY, and EBITDA margin expanded 180bp YoY to 14.9%, driven by improved ASPs across both the Auto and FES segments.
- Management remains confident of outperforming the UV industry in FY26, driven by new launches like Thar Roxx, XUV 3XO, and recent EVs. It plans to boost UV capacity to 69k/85K units in FY26/FY27, with a greenfield project for future needs beyond FY28.
- We believe MM is well-placed to outperform across its core business, driven by healthy recovery in rural areas and new product launches across both UV and tractor segments. We estimate MM to post CAGR of 13%/13%/18% in revenue/EBITDA/PAT over FY25–27E.

Key Rationales

- HAL is a market leader in aerospace defense. It boasts a strong order book of ₹1.8t as of Mar'25, along with a promising prospect pipeline of ₹6t, which is likely to be awarded over next few years.
- HAL is transitioning from traditional licensed model to indigenized model and is currently working on marque projects such as Tejas Mk1, Tejas Mk1a, Su-30 upgrade, Dornier-25, and LUH, et al.
- Near-term catalysts will emerge with aircraft deliveries as GE engine supplies resumes for Tejas Mk1A from FY26, while medium to long term triggers hinge on order finalization for 97 Tejas Mk1A, Tejas Mk-II, LUH & others. We estimate 29%/33%/29% revenue/EBITDA/PAT CAGR over FY25–27.



**Building blocks;
outperformance to
sustain**



**Steady quarter; robust
other income drives
earnings beat**

Key Rationales

- Divi has the skill set across building blocks, fragments, and the polymer level for peptides. It has the capability for solid as well as liquid phase synthesis, thereby providing multiple service offerings to innovator customers.
- Divi's is targeting growth-driven CS segments like peptides & contrast media, where product complexity plays to its strengths. With its proven capabilities, the company is ideally placed to gain a competitive edge and maximize commercial success in these areas.
- We estimate 25% earnings CAGR over FY25-27, driven by improved capacity utilization and healthy traction across key segments.

Key Rationales

- Mankind's focus on a differentiated portfolio, comprising: a) prescription products (including the recently acquired BSV), b) consumer wellness, and c) exports, positions the company for robust growth over the next 4-5 years.
- Mankind expects single-digit revenue growth for BSV in FY25, followed by 15%+ growth in FY26 with margins of 26-28%. Over the next 2-3 years, margins are projected to reach ~30%.
- We expect a 20% earnings CAGR over FY25-27, supported by its strong focus on chronic therapies (niche) and exports.

Key Rationales

- MAXH is well-positioned as a leading multi-specialty hospital chain, with plans to add 3,600+ beds over 3-4 years through brownfield expansion and strategic acquisitions.
- The Jaypee Hospital acquisition boosts its North India presence, while rising insurance coverage, PPPs, and medical infra investments support long-term growth.
- We expect strong 26% YoY revenue growth in Q4FY25, aided by volume expansion and 42% YoY growth in Max Labs, with improving margins. Lower ARPOB of ₹73.8K reflects scale-driven growth; ramp-up of Lucknow, Nagpur, and Jaypee units to enhance profitability and reach. We expect a 17%/24% revenue/PAT CAGR over FY25-27.



**Building blocks;
outperformance to
sustain**



**Building blocks;
outperformance to
sustain**



**Steady quarter; robust
other income drives
earnings beat**

Key Rationales

- KAYNES is expanding into North America, Europe, and South Asia, focusing on ODM and high-margin businesses. Capex of INR23b for semiconductor projects is supported by government subsidies.
- Orders from industrials, EVs, aerospace, and automotive sectors are expected to materialize from FY26. Smart Meters, Railways, and Semiconductor projects (OSAT, HDIPCB) are key growth drivers, with significant revenue contributions from FY26 onwards.
- With a projected 56%/62%/68% CAGR in revenue/EBITDA/PAT over FY24-27, we reiterate BUY, citing margin expansion led by increased traction in high-margin verticals.

Key Rationales

- JKCE plans to double its grey cement capacity by FY30 through greenfield and brownfield projects across North, Central, South, and East India. This expansion will strengthen its market position and enhance its pan-India presence.
- The company is improving its cost structure with efficient equipment, upgrades, and sustainability measures like increasing green power and Thermal Substitution Rate (TSR). It has delivered robust volume (grey cement) CAGR of ~16% over FY20-25.
- We estimate JKCE's revenue/EBITDA/PAT CAGR at 15%/21%/33% over FY25-27, driven by strong volume growth and profitability. We maintain a buy, as JKCE is well-positioned among mid-sized cement firms.

Key Rationales

- The Cables & Wires (C&W) business saw healthy demand and margin gains, while the FMEG segment turned profitable, aided by richer mix and better cost absorption.
- 4QFY25 revenue grew ~25% YoY to INR69.9b, with EBITDA up 35% YoY and margin expanding 110bps to 14.7%. PAT rose 33% YoY to INR7.3b, aided by lower interest costs and higher other income.
- We expected 16%+ CAGR in revenue/EBITDA/PAT over FY25-27 and improving free cash flow, Polycab remains well-positioned for sustainable growth. We reiterate our BUY rating on Polycab (40x FY27E EPS), as strong execution across segments drove robust performance.



**Building blocks;
outperformance to
sustain**

Key Rationales

- Tata Consumer reported 17% YoY revenue growth in 4QFY25, though EBIT fell 9% due to tea cost inflation. Margins improved QoQ on price hikes in tea/salt, with early signs of better tea crop aiding recovery.
- India branded biz grew 18% (UVG +5.9%), but EBIT dropped 25% on input costs. International biz revenue rose 13%, while non-branded biz EBIT surged 22%. NourishCo (RTD) grew 10%, and Starbucks revenue rose 5% YoY.
- Management expects margin recovery via calibrated price hikes (offsetting 30-40% of tea cost inflation) and targets mid-single-digit volume growth in FY26. Synergies from Capital Foods/Organic India integration to drive growth. We forecast 8%/13%/20% revenue/EBITDA/PAT CAGR over FY25-27.

Key Rationales

- VBL delivered strong 1QCY24 performance with 29% YoY revenue growth, driven by robust 30% volume growth (15.5% organic). Domestic demand stayed healthy with double-digit growth.
- Management remains confident in long-term double-digit volume growth, supported by distribution expansion (visi-coolers) and a shift towards healthier beverages (nimbooz +100% YoY). International markets, though margin-dilutive, offer scale-up potential.
- We maintain BUY (55x CY26E EPS), projecting 18%/16%/26% revenue/EBITDA/PAT CAGRs over CY25-26. As PepsiCo's key franchisee, VBL is well-placed to capitalize on India's underpenetrated beverage market and rural refrigeration growth.

Key Rationales

- Eternal's Q4 performance was driven by Blinkit's explosive GOV growth (+134% YoY), though profitability remains pressured by aggressive dark-store expansion and rising competition.
- While food delivery showed stable 16% YoY GOV growth, Blinkit's EBITDA losses widened (-2.4% of NOV) due to customer acquisition costs and underutilized stores. Management expects competitive intensity to persist, delaying Blinkit's breakeven to FY27.
- However, the long-term opportunity in quick commerce remains compelling, with Eternal well-positioned as a market leader. We maintain our BUY rating, as we believe Blinkit's scale and first-mover advantage justify near-term losses. Investors should brace for volatility but stay focused on the structural growth story.



**Steady quarter; robust
other income drives
earnings beat**



**Building blocks;
outperformance to
sustain**



**Building blocks;
outperformance to
sustain**

Key Rationales



**Steady quarter; robust
other income drives
earnings beat**

- Castrol reported in-line 1QCY25 results, with revenue at ~INR14.2b, EBITDA at INR3b (up 5% YoY), and PAT at INR2.3b. Volumes stood at 62m liters, in line with estimates. Gross margin dipped 423bp QoQ but was flat YoY.
- Management remains bullish on India's lubricant demand, given India's low car penetration, targeting above-industry growth (4-5%) and a 22-25% EBITDA margin.
- Growth will be driven by brand relaunches (e.g., Castrol Activ), new product traction, expanding distribution (~148,000 outlets). We estimate EBITDA margins of ~23% for both CY25/CY26, reflecting confidence in profitability and growth.

Key Rationales



**Building blocks;
outperformance to
sustain**

- HPCL reported EBITDA 61% above estimates, driven by stronger-than-expected GRM of USD8.5/bbl. and marketing margin of INR4.5/lit, leading to PAT of INR33.5b, (+114% beat).
- HPCL's gas sales volume stood at 1mmt+ (+40% YoY). It expects 25-30% YoY growth in volumes. The OMC rally may be nearing its end, but near-term drivers persist: LPG price hike, rising Russian crude intake, & steady marketing margins.
- We favour HPCL for its marketing leverage, dividend appeal, & upcoming project ramp-ups. We estimate FY26E RoE of 17.3%, key catalysts: de-merger & potential listing of the lubricant business, start up of Rajasthan refinery in FY26, & improving LPG under-recovery dynamics.

Key Rationales



**Building blocks;
outperformance to
sustain**

- Power Grid remains well-positioned for long-term growth, backed by a robust order book (~₹1.43T), rising capex (₹280-300B guided for FY26), and strong execution capabilities.
- Higher capital expenditure may moderate near-term dividends, the company's leadership in transmission and strategic focus on renewable energy integration (500GW non-fossil target) support sustained growth.
- The company continues to secure key projects, expand its cust. base, and innovate through green initiatives and digital upgrades. With a strong project pipeline, it is well-positioned to capitalize on the multi-year transmission capex upcycle. Stock's valuation remains attractive given its growth trajectory. Reiterate BUY.



**Steady quarter; robust
other income drives
earnings beat**

Key Rationales

- IHCL reported strong Q4 with revenue up 27% YoY, backed by double-digit RevPAR growth, rising FTAs, and strong MICE and leisure travel demand.
- Its aggressive expansion plans, with 30 new hotels and a 15,900-room pipeline, along with INR12b capex for asset upgrades and greenfield projects in FY26, well-positioned to sustain double-digit revenue growth which further strengthen the growth story.
- With a healthy mix of domestic and international momentum, and EBITDA/PAT CAGR of 22% over FY25–27E, IHCL is set to deliver sustained shareholder value, supported by a strong industry outlook and robust execution.



**Building blocks;
outperformance to
sustain**

Key Rationales

- Amber, a leading RAC and components manufacturer, is seeing strong demand across RAC and EMS segments, supported by new client additions and domestic manufacturing tailwinds.
- It is scaling its EMS capabilities via a ₹6.5B investment in Ascent Circuits and a PLI-linked JV with Korea Circuit. Key monitorables include EMS margin trajectory, demand in RAC/non-RAC segments, and progress in the railway electronics segment.
- For 4QFY25, we expect revenue to grow 10% YoY and PAT to rise 37% YoY, with EBITDA margin expanding 20bp YoY to 8.1%. We estimate a revenue/EBITDA/PAT CAGR of 26%/33%/62% over FY24–27

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).
Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>
Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishView/Litigation.aspx>
MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.
To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule I to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited, ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai- 400025; Tel No: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com. Contact No: 022- 40548085.

Grievance Redressal Cell:	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): IN2000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent - CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp.grievances@motilaloswal.com.